Trending...
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
WILMINGTON, N.C., May 5, 2021 /PRNewswire/ -- Isosceles Pharmaceuticals Inc. a biotechnology company dedicated to developing, commercializing, and marketing innovative non-opioid products for the treatment of mild to moderate pain and inflammatory diseases, today announced the appointment of William D. Humphries as its Chief Executive Officer. Mr. Humphries is a highly accomplished executive leader in the pharmaceutical industry with a proven track record leading several global pharmaceutical companies.
"We are excited to welcome Bill for the role of Chief Executive Officer," said Tim Wright, Chairman of Isosceles Board of Directors. "His extensive background in the pharmaceutical industry will provide invaluable leadership as Isosceles achieves its strategic growth milestones."
Most recently, Mr. Humphries served as President of Ortho Dermatologics, a subsidiary of Bausch Health Companies. He has also held global executive leadership positions at Merz North America, GlaxoSmithKline, Stiefel, and Allergan.
"I would like to thank Tim and the Isosceles team for welcoming me to company," said Mr. Humphries, Chief Executive Officer of Isosceles. "I was attracted to Isosceles by their focus on the pursuit of innovative solutions for safe, novel non-opioid pain relief and the passion the team has for delivering these important products to the market. I look forward to leveraging my experience to accelerate the company's development plans and lead Isosceles as it unlocks its full potential."
More on ncarol.com
Mr. Humphries currently serves as Chairman of the Board at Clearside Biomedical, Chairman of the North Carolina State University Global Luxury Management Board, is a member of the Board at Aclaris Therapeutics, and a member of the Board at Strata Skin Sciences. He received his MBA from Pepperdine University and completed his undergraduate studies at Bucknell University.
About Isosceles Pharmaceuticals, Inc.
Isosceles Pharmaceuticals is a preclinical stage biotechnology and medical device company focused on the delivery of drug master file backed synthetic cannabinoids for their anti-inflammatory and pain relief properties. The Company's proprietary formulations coupled with unique delivery platforms provide high bioavailability via parenteral and transdermal routes.
Investor Contact
Brett Lanier
[email protected]
SOURCE Isosceles Pharmaceuticals, Inc.
Related Links
www.isoscelespharma.com
"We are excited to welcome Bill for the role of Chief Executive Officer," said Tim Wright, Chairman of Isosceles Board of Directors. "His extensive background in the pharmaceutical industry will provide invaluable leadership as Isosceles achieves its strategic growth milestones."
Most recently, Mr. Humphries served as President of Ortho Dermatologics, a subsidiary of Bausch Health Companies. He has also held global executive leadership positions at Merz North America, GlaxoSmithKline, Stiefel, and Allergan.
"I would like to thank Tim and the Isosceles team for welcoming me to company," said Mr. Humphries, Chief Executive Officer of Isosceles. "I was attracted to Isosceles by their focus on the pursuit of innovative solutions for safe, novel non-opioid pain relief and the passion the team has for delivering these important products to the market. I look forward to leveraging my experience to accelerate the company's development plans and lead Isosceles as it unlocks its full potential."
More on ncarol.com
- Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
- IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
- AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
- Surging Into Hyper-Growth Mode With Record Revenue, Raised 2026 Guidance, and Game-Changing AI Platform; Off The Hook YS (NYSE American: OTH)
- Mom Creators Coalition Launches with WaterWipes® as Official Founding Sponsor
Mr. Humphries currently serves as Chairman of the Board at Clearside Biomedical, Chairman of the North Carolina State University Global Luxury Management Board, is a member of the Board at Aclaris Therapeutics, and a member of the Board at Strata Skin Sciences. He received his MBA from Pepperdine University and completed his undergraduate studies at Bucknell University.
About Isosceles Pharmaceuticals, Inc.
Isosceles Pharmaceuticals is a preclinical stage biotechnology and medical device company focused on the delivery of drug master file backed synthetic cannabinoids for their anti-inflammatory and pain relief properties. The Company's proprietary formulations coupled with unique delivery platforms provide high bioavailability via parenteral and transdermal routes.
Investor Contact
Brett Lanier
[email protected]
SOURCE Isosceles Pharmaceuticals, Inc.
Related Links
www.isoscelespharma.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him
- NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
- Nufabrx Added to TrillaMed Pharmacy and DAPA Contracts
- DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
- CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
- Explosive $10 Billion Counter-Drone Market with AI-Powered Defense Ecosystem: ZenaTech, Inc. (N A S D A Q: ZENA)
- High-Value Execution Phase Begins: Bitcoin Bancorp Ignites Texas Rollout of Digital Asset ATM Network: Bitcoin Bancorp (Stock Symbol: BCBC) $BCBC
- UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
- SelfCare is now HealthCare across America
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
- GDE Tree Services Expands Operations into Sydney, NSW
- Tuckwell Machinery Expands CNC Range to Support Australian Cabinet Makers
- The Inner Power of Emotional Self-Leadership
- Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
- Over 98% of crypto owners globally don't declare taxes, new report find
- TicTac Group acquires French EdTech company Distrisoft